One mixed result from a phase I clinical trial (NCT02428309) using polyclonal Tregs in SLE found that the administered Tregs were able to traffic to the site of autoimmunity, in this case the skin, yet there was an increase in pro-inflammatory IL-17 from CD4+ and CD8+ cells [88]. The gene discussed is CD4; the disease is Autoimmunity.